The New York Times

Despite long-established procedures for bringing Americans home for monitoring and treatment, the Trump administration has not said that it will allow those at risk of Ebola back into the country.

Secretary of State Marco Rubio indicated in pointed testimony to senators that he was reclaiming control of the U.S. relationship with Gavi, an international vaccine alliance.

A Mellon heir transferred the adjacent Connecticut properties, covering about 300 acres, at no cost to Children’s Health Defense last year.

A chronic lack of investment in development of better tests has left clinicians blind and allows deadly viruses to spread unchecked.

The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a rapidly widening epidemic in Africa.

Thousands of mysterious containers lie scattered across northern Laos. These “death jars” may have provided a form of communal interment, archaeologists reported.

Despite widespread support in polls, the number of people who actually go through with the practice remains very small.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.

His research showing the positive effects of athletics on intellectually disabled children led Eunice Kennedy Shriver to ask him to help stage the Games.

The order came after U.S. officials said that a 50-bed facility was being established in the African country to house American citizens exposed to the virus.

The babies were part of a vaccine trial for a respiratory virus in the 1960s and died shortly after. Their families said they had been unaware of the trial until recently.

As predictive medicine advances, legal scholars warn that decades-old federal guidelines could set up a potential clash between your genes and your job.

Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these patients.

Drew Altman, who transformed KFF from a little-known family foundation to a major source of U.S. health policy research, will step down at the end of the year.